Global Preventive Vaccines Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Vaccine Type;

Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vector Vaccines, DNA Vaccines, and Others.

By Disease Indication;

Pneumococcal Vaccines, Poliovirus, Hepatitis, Influenza, Measles, Mumps, Rubella (MMR), Varicella, Human Papilloma Virus, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn441549767 Published Date: October, 2024 Updated Date: November, 2024

Introduction

Global Preventive Vaccines Market (USD Million), 2020 - 2030

In the year 2023, the Global Preventive Vaccines Market was valued at USD 64,281.64 million. The size of this market is expected to increase to USD 135,662.67 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 11.3%.

The Global Preventive Vaccines Market is a dynamic and rapidly evolving sector within the broader pharmaceutical industry, primarily focused on the development and distribution of vaccines designed to prevent infectious diseases. This market is driven by the increasing awareness of the importance of immunization in maintaining public health, reducing healthcare costs, and preventing the spread of contagious diseases. Vaccines are biological preparations that provide immunity against specific pathogens, and their development involves rigorous research, extensive clinical trials, and stringent regulatory approvals to ensure their safety and efficacy.

In recent years, the preventive vaccines market has witnessed significant growth, propelled by advancements in biotechnology, increased investment in research and development, and the urgent need to combat emerging infectious diseases, such as COVID-19. The pandemic underscored the critical role vaccines play in controlling outbreaks, leading to unprecedented global collaboration and rapid innovation in vaccine technology, including mRNA vaccines. This has not only accelerated the development timelines but also broadened the scope of vaccine platforms and delivery methods, making vaccines more accessible and effective.

The market is characterized by a diverse range of stakeholders, including pharmaceutical companies, biotech firms, government agencies, and non-governmental organizations, all working collaboratively to enhance vaccine coverage and equity. Additionally, initiatives such as the Global Vaccine Action Plan and the COVAX facility aim to ensure that vaccines reach populations in low- and middle-income countries, addressing disparities in healthcare access. As the market continues to expand, it faces challenges such as vaccine hesitancy, supply chain logistics, and the need for continuous monitoring of vaccine safety and effectiveness. However, the ongoing innovations and concerted global efforts present a promising future for the preventive vaccines market, with the potential to significantly improve global health outcomes.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Vaccine Type
    2. Market Snapshot, By Disease Indication
    3. Market Snapshot, By Region
  4. Global Preventive Vaccines Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Immunization
        2. Disease Prevention
        3. Public Health Initiatives
        4. Research and Development
      2. Restraints
        1. Vaccine Hesitancy
        2. Supply Chain Challenges
        3. Regulatory Barriers
        4. Affordability and Accessibility
      3. Opportunities
        1. Expanded Market Reach
        2. Technological Advancements
        3. Public-Private Partnerships
        4. Pandemic Preparedness Investments
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Preventive Vaccines Market, By Vaccine Type, 2020 - 2030 (USD Million)
      1. Live/Attenuated Vaccines
      2. Inactivated Vaccines
      3. Subunit Vaccines
      4. Toxoid Vaccines
      5. Conjugate Vaccines
      6. Recombinant Vector Vaccines
      7. DNA Vaccines
      8. Others
    2. Global Preventive Vaccines Market, By Disease Indication, 2020 - 2030 (USD Million)
      1. Pneumococcal Vaccines
      2. Poliovirus
      3. Hepatitis
      4. Influenza
      5. Measles
      6. Mumps
      7. Rubella (MMR)
      8. Varicella
      9. Human Papilloma Virus
      10. Others
    3. Global Preventive Vaccines Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca Plc
      2. Emergent Biosolutions
      3. GeoVax
      4. GlaxoSmithKline Plc
      5. Inovio Pharmaceuticals
      6. Johnson & Johnson
      7. Merck & Co., Inc.
      8. Novartis AG
      9. Pfizer
      10. Sanofi S.A.
  7. Analyst Views
  8. Future Outlook of the Market